title: Smoking and drinking habits are important predictors of Helicobacter pylori eradication.
abstract: OBJECTIVE
  The aim of the study was to evaluate the effect of smoking and drinking habits, in separate and joint analyses, on the efficacy of H. pylori eradication.
  
  
  METHODS
  A total of 250 patients were recruited. They were treated with a 7-day course of omeprazole, amoxicillin, tinidazole (OAT), omeprazole amoxicillin, clarithromycin (OAC) or omeprazole, clarithromycin, tinidazole (OCT). The efficacy of H. pylori eradication was tested with a CLO-test and histology 4 weeks after the completion of antibacterial therapy.
  
  
  RESULTS
  Drinking was found not to affect the efficacy of H. pylori eradication in any therapeutic group, while smoking decreased it in the OAC group (smokers 69.6%, non-smokers 94.3%, p=0.006). In the OAT treated group H. pylori eradication rate was lower in smokers-non-drinkers than in smokers-drinkers and non-smokers-non-drinkers (38.9% vs 83.2% and 70.0%, p=0.002 and p=0.034, respectively), while in the OAC treated group, smokers-non-drinkers had lower eradication efficacy than non-smokers-drinkers and non-smokers-non-drinkers (59.1% vs 100% and 91.3%, p=0.01 and p=0.012, respectively). In the OCT treated group, differences between subgroups were not significant.
  
  
  CONCLUSIONS
  Smoking and drinking habits when analyzed jointly are more useful to predict the outcome of H. pylori eradication than when analyzed separately.
authors.affiliation: Department of Prosthetic Dentistry, Medical University of Białystok, and Department of Medicine and Gastroenterology, District Hospital, Białystok, Poland.
authors.forename: D B
authors.initials: DB
authors.lastname: Namiot
authors.forename: K
authors.initials: K
authors.lastname: Leszczyńska
authors.forename: Z
authors.initials: Z
authors.lastname: Namiot
authors.forename: A J
authors.initials: AJ
authors.lastname: Kurylonek
authors.forename: A
authors.initials: A
authors.lastname: Kemona
mesh_terms: D000428:Alcohol Drinking / Q000453:epidemiology*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology*; D011237:Predictive Value of Tests; D012907:Smoking / Q000453:epidemiology*
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents